medigraphic.com
ISSN 2594-1518 (Electronic)
ISSN 1405-0099 (Print)

2006, Number 3

<< Back Next >>

Cir Gen 2006; 28 (3)

Pancreatoduodenectomy as an alternative in the management of a non-functioning neuroendocrine tumor of the pancreas

Echeverría-Miranda CA, Gómez-Gómez E, Carrillo-Ponce CS, Mondragón-Sánchez A, Mondragón-Sánchez R

Language: Spanish
References: 12
Page: 188-192
PDF size: 74.21 Kb.


ABSTRACT

Introduction: Neuroendocrine tumors of the pancreas are rare neoplasms. More than half of them are functioning and are diagnosed early based on the secreted substance. Non-functioning lesions are diagnosed lately due to their unspecific symptomatology.
Objective: To present the case of a woman in whom a non-functional endocrine neoplasm was diagnosed, located in the head of the pancreas and to discuss the different ways of handling this neoplasm.
Case description: Woman, 23 years of age, with a history of 3 months of evolution with intense pruritus, weight loss, jaundice, colic-type pain in the right hypochondrium, nocturnal diaphoresis, and fever, who was referred to our hospital for definitive management. Laboratory tests revealed data of extrahepatic cholestasis. Computed tomography revealed a hypodense lesion of 6 cm in diameter. She was subjected to pancreatoduodenectomy. Immunohistochemical studies were difusely positive to chromatogranin A, synaptophysin, and neuron-specific enolose. After 2 years of follow-up the patient is asymptomatic, without evidence of tumor recurrence.
Conclusions: Radical surgical treatment is the best way to handle this entity, as it eliminates the symptoms in this type of patients, improving their quality of life and survival.


REFERENCES

  1. Remage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54 Suppl 4: iv1-16.

  2. Mondragón-Sánchez RJ, Castillero-Pinilla C, Saldivar-Moreno C, Oñate- Ocaña LF, Ruiz-Molina JM, Aielllo-Crocifoglio V. Management of digestive system carcinoid tumors and carcinoid syndrome. Rev Gastroenterol Méx 1998; 63: 204-210.

  3. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumours: a nation-wide epidemiologic study from Sweden. Cancer 2001; 92: 2204-10.

  4. Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical oncologist’s perspective. Surg Clin North Am 2001; 81: 527-42.

  5. Obara T, Shudo R, Fujii T, Tanno S, Mizukami Y, Izawa T, et al. Pancreatic duct obstruction caused by malignant islet cell tumors of the pancreas. Gastrointest Endosc 2000; 51: 604-7.

  6. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 1991; 36: 933-42.

  7. Heller SJ, Ferrari AP, Carr-Locke DL, Lichtenstein DR, Van Dam J, Banks PA. Pancreatic duct stricture caused by islet cell tumors. Am J Gastroenterol 1996; 91: 147-50.

  8. Kloppel G, Heitz PU, Capella C, Solcia E. Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg 1996; 20: 132-41.

  9. Falconi M, Bettini R, Scarpa A, Capelli P, Pederzoli P. Surgical strategy in the treatment of gastrointestinal neuroendocrine tumours. Ann Oncol 2001; 12: S101-3.

  10. Kloppel G. Tumours of the endocrine pancreas. Pathologe 2003; 24: 265-71.

  11. Ardengh JC, de Paulo GA, Ferrari AP. EUS-guiaded FNA in the diagnosis of pancreatic neuroendocrine tumors before surgery. Gastrointest Endosc 2004; 60: 378-84.

  12. Spivach A, Turoldo A, Zanconati F, Colautti I. Non-functioning neuroendocrine tumor of the pancreas: report of a




2020     |     www.medigraphic.com